BTK inhibitors, such as Acalabrutinib and Ibrutinib, are FDA‐approved for CLL and mantle cell lymphoma, with Acalabrutinib showing improved specificity. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.